Congratulations to Jiangxi Rimag Group Co.,Ltd. (2522.HK) on its Successful Listing

Congratulations to Jiangxi Rimag Group Co.,Ltd. (2522.HK) on its successful listing on the Mainboard of HKSE on 7 June 2024.

 

Jiangxi Rimag Group Co.,Ltd. (“Rimag”) , a prominent medical group in China specializing in medical imaging, is the sole operator and manager of a comprehensive medical imaging platform offering diverse services and value across the entire industry chain in China. Rimag mainly compete in the PRC third-party medical imaging center market, a fast-growing segment whose market size grew at a CAGR of 29.0% from 2018 to 2023 and is expected to grow with a CAGR of 33.5% from 2023 to 2026, far exceeding that of 12.9% and 14.3% of the PRC medical imaging service market during the same periods, respectively.

 

With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services in relation to preferred shares, employee stock plan, M&A transactions, financial assets, goodwill and asset impairment tests and expected credit losses.

 

Congratulations again to Jiangxi Rimag Group Co.,Ltd. (2522.HK) on its successful listing. The issue price is HKD14.98 per share and the amount of funds raised is HKD266.88 million.